 BRYAN, Texas, July 08, 2021 GLOBE NEWSWIRE -- iBio, Inc. NYSEA:IBIO iBio or the Company, a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming Protein Expression System by announcing today it is adding three anti-cancer targets to its pipeline of therapeutic candidates. This development establishes the Companys new drug discovery capabilities announced just a few weeks ago. 